. Author manuscript; available in PMC: 2011 Jul 15.

Published in final edited form as: Pediatr Blood Cancer. 2010 Jul 15;55(1):119–122. doi: 10.1002/pbc.22529

Table II.

Characteristics of the studies and number of subjects consenting to optional pharmacokinetic

		Number of Studies	Number (percent) of subjects agreeing to pharmacokinetic sampling	Number (percent) of subjects not agreeing to pharmacokinetic sampling
Route of study drug administration	IV	21	16 (76)	5 (24)
Route of study drug administration	PO	29	20 (69)	9 (31)
Additional IV required for pharmacokinetic sampling	No	23	17 (74)	6 (26)
Additional IV required for pharmacokinetic sampling	Yes	27	19 (70)	8 (30)
Additional time required for pharmacokinetic sampling	No	5	4 (80)	1 (20)
Additional time required for pharmacokinetic sampling	Yes	45	32 (71)	13 (29)
1–4 hrs (n=11)			11 (100)	-
4–8 hrs (n=9)			6 (67)	3 (33)
8–12 hrs (n=5)			4 (80)	1 (20)
Overnight (n=1)			1 (100)	-
Extra visit (n=19)			10 (53)	9 (47)